Applications published 3 June 2009

Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
Echo Pharmaceuticals 2063861*

Pharmaceutical formulations for use in HIV therapy
Matrix Laboratories 2063862*

• Drug electrotransport with hydration measurement of hydratable reservoir
ALZ Corp 2063863*

• Long-term 24-hour intestinal administration of levodopa/carbidopa
Solvay Pharmaceuticals 2063865*

• Preparation of glassified biological reagents
GE Healthcare Bio-Sciences 2063866*

• Pharmaceutical compsns for treatment of Parkinson's disease and related disorders
Combinatorx 2063867*

• Pharmaceutical compsns containing rosuvastatin calcium
Richter Gedeon 2063868*

• Oral modified release formulations
Bayer Schering Pharma 2063870*

• Controlled release solid oral dosage formulations comprising nisoldipine
Jagotech 2063871*

• Controlled release oral dosage formulations comprising a core and one or more barrier layers
Jagotec 2063872*

• NSAID dose unit formulations with H2-receptor antagonists and methods of use
Horizon Therapeutics 2063873*

• Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby
SK Chemicals; Ewha University-Industry Collaboration Foundation 2063874*

• Combination pharmaceutical compsns
Sigmoid Pharma 2063875*

• Extended release pharmaceutical formulation of metoprolol and process for its preparation
Farmaprojects 2063876*

• Drugs comprising an inhibitor of class 1 alpha mannosidase for the treatment of sarcoglycanopathies
Genethon 2063877*

• Bisthiohydrazine amides) for use in preventing or delaying the recurrence of melanoma
Synta Pharmaceuticals 2063878*

• Compsns of CHK1 inhibitors and cyclodextrin
ICOS  2063879*

• Compsn for the treatment of amyotrophic lateral sclerosis
GEMAC 2063880*

• A compsn and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
Ko, Young Hee 2063881*

• Tyrosine kinase inhibitors for prevention or treatment of infection
Emory University 2063882*

• Binding interaction of proanthocyanidins with bacteria and bacterial components
The Government of the United States of America as represented by the Secretary of the Navy 2063883*

• Pro-oxidant anti-cancer compounds
Ralph, Stephen John; Neuzil, Jiri 2063884*

• Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
Merck 2063885*

• Use of N-containing spirocompounds of N-compounds for the enhancement of cognitive function
Adolor 2063886*

• New small molecule inhibitors of MDM2 and the uses thereof
The Regents of the University of Michigan 2063887*

• Pharmaceutical compsn comprising candestan cilexetil
AstraZeneca 2063888*

• Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
Merck; Sunesis Pharmaceuticals 2063889*

• Combination treatment for diabetes mellitus
Nycomed 2063890*

• Indoquinoline compounds as calcium channel blockers
Medipropharma 2063891*

• Methods and compsns for treating amyotrophic lateral sclerosis (ALS)
Medivation Neurology 2063892*

• 3,4-dihydro-2 (1H)-quinoline and 2 (1H)-quinoline derivatives
Concert Pharmaceuticals 2063893*

• Formulations containing pyridazine compounds for treating neuroinflammatory diseases
The Regents of Northwestern University 2063894*

• Combination drug
Takeda Pharmaceutical Company 2063895*

• Kinase inhibitors useful for the treatment of proliferative diseases
Deciphera Pharmaceuticals 2063896*

• Kinase inhibitors useful for the treatment of proliferative diseases
Deciphera Pharmaceuticals 2063897*

• Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
Brigham Young University; Colorado State University Research Foundation; Children's Hospital Medical Centre 2063898*

• Use of vitamin D compounds for the prevention of adhesions
Bioxell 2063899*

• A cancer sensitiser comprising glucosamine, glucosamine derivatives or salts thereof
National Cancer Centre 2063900*

• Novel triclosan salts
Tyco Healthcare Group 2063901*

• Therapeutic cell medicine comprising skin tissue derived stem cell
Pusan National University Industry-University Cooperation Foundation 2063902*

• Pulmonary surfactant formulations and methods for promoting mucus clearance
Discovery Laboratories 2063903*

• Methods involving LEF-1 regulation and use of LEF-1 or compounds altering LEF0-1 signalling for treating and preventing diseases
Medizinische Hochschule Hannover 2063904*

• Treatment of liver disorders by administration of receptor-associated protein (RAP)-conjugates
Raptor Pharmaceutical 2063905*

• Methods and compsns for promoting organ development
Kintan 2063906*

• Methods and compsns based on diphtheria toxin-interleukin-3 conjugates
Frankel, Arthur 2063907*

• Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
Protaffin Biotechnologie 2063908*

• Formulations for therapeutic adminstration of thyroid stimulating hormone (TSH)
Genzyme 2063909*

• Method of treating endothelial dysfunction
Orthologic; The Texas A&M University System 2063910*

• Immunogenic compsns for gram positive bacteria
Novartis 2063911*

• Polyalkylene oxides having hindered ester-based biodegradable linkers
Enzon Pharmaceuticals 2063912*

• Antigenic protein conjugates and process for preparing same
Abbott Laboratories 2063913*

• Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation
Zentiva 2063914*

• Fluorogenic protein kinase substrates
Invitrogen 2063915*

• X-ray contrast agent for post-mortem experimental and diagnostic angiography
Forim-X 2063916*